RI
RTW Investments Portfolio holdings
AUM
$7.02B
This Quarter Return
+31.86%
1 Year Return
+28.16%
3 Year Return
+245.48%
5 Year Return
+425.65%
10 Year Return
+5,642.23%
AUM
$6.4B
AUM Growth
+$6.4B
(+35%)
Cap. Flow
+$641M
Cap. Flow
% of AUM
10.02%
Top 10 Holdings %
Top 10 Hldgs %
53.23%
Holding
81
New
14
Increased
12
Reduced
20
Closed
17
Top Buys
| 1 |
Arvinas
ARVN
|
$173M |
| 2 |
CRGX
CARGO Therapeutics
CRGX
|
$120M |
| 3 |
Madrigal Pharmaceuticals
MDGL
|
$117M |
| 4 |
Akero Therapeutics
AKRO
|
$83.9M |
| 5 |
Alkermes
ALKS
|
$83.6M |
Top Sells
| 1 |
Thermo Fisher Scientific
TMO
|
$128M |
| 2 |
MoonLake Immunotherapeutics
MLTX
|
$28.5M |
| 3 |
Illumina
ILMN
|
$25.8M |
| 4 |
AXNX
Axonics, Inc. Common Stock
AXNX
|
$24.8M |
| 5 |
scPharmaceuticals
SCPH
|
$23.5M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Financials | 0.02% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Rocket Pharmaceuticals
RCKT
$354M
| $530M | 8.28% | 17,687,772 | – | – |
|
2
Immunocore
IMCR
$1.62B
| $417M | 6.51% | 6,096,387 | – | – |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $398M | 6.21% | 6,768,514 | – | – |
|
4
Axsome Therapeutics
AXSM
$6.05B
| $357M | 5.58% | 4,489,596 | – | – |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $352M | 5.5% | 11,253,551 -322,986 | -3% | -$10.1M |
|
6
Ultragenyx Pharmaceutical
RARE
$2.89B
| $329M | 5.14% | 6,887,086 +1,481,997 | +27% | +$70.9M |
|
7
Alnylam Pharmaceuticals
ALNY
$58.5B
| $314M | 4.91% | 1,640,559 -42,803 | -3% | -$8.19M |
|
8
argenx
ARGX
$43.6B
| $254M | 3.96% | 667,195 +160,000 | +32% | +$60.9M |
|
9
Bruker
BRKR
$5.16B
| $246M | 3.84% | 3,344,095 -37,608 | -1% | -$2.76M |
|
10
Cytokinetics
CYTK
$4.23B
| $211M | 3.29% | 2,525,080 -49,118 | -2% | -$4.1M |
|
11
PTC Therapeutics
PTCT
$3.92B
| $205M | 3.2% | 7,423,970 +188,774 | +3% | +$5.2M |
|
|
12
Madrigal Pharmaceuticals
MDGL
$9.76B
| $189M | 2.95% | 815,191 +505,706 | +163% | +$117M |
|
|
13
Arvinas
ARVN
$568M
| $173M | 2.71% | +4,213,483 | New | +$173M |
|
14
Masimo
MASI
$7.59B
| $171M | 2.68% | 1,462,400 -39,093 | -3% | -$4.58M |
|
15
Penumbra
PEN
$10.6B
| $167M | 2.6% | 662,664 -10,707 | -2% | -$2.69M |
|
16
Natera
NTRA
$23.1B
| $162M | 2.54% | 2,593,323 -58,460 | -2% | -$3.66M |
|
17
Celldex Therapeutics
CLDX
$1.47B
| $137M | 2.15% | 3,463,201 | – | – |
|
18
Protagonist Therapeutics
PTGX
$3.67B
| $122M | 1.9% | 5,315,514 -100,000 | -2% | -$2.29M |
|
|
CRGX
19
DELISTED
CARGO Therapeutics
CRGX
| $120M | 1.87% | +5,175,832 | New | +$120M |
|
20
Vericel Corp
VCEL
$1.83B
| $114M | 1.79% | 3,212,794 -79,079 | -2% | -$2.82M |
|
|
SAGE
21
DELISTED
Sage Therapeutics
SAGE
| $113M | 1.76% | 5,197,019 +47,537 | +0.9% | +$1.03M |
|
|
22
Alkermes
ALKS
$4.78B
| $108M | 1.69% | 3,901,523 +3,012,450 | +339% | +$83.6M |
|
|
AVDL
23
Avadel Pharmaceuticals
AVDL
$1.43B
| $98.1M | 1.53% | 6,947,918 -188,497 | -3% | -$2.66M |
|
24
10x Genomics
TXG
$1.74B
| $86.7M | 1.35% | 1,549,951 +29,995 | +2% | +$1.68M |
|
|
25
Akero Therapeutics
AKRO
$3.74B
| $83.9M | 1.31% | +3,592,759 | New | +$83.9M |
|